Cargando…
Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI
The outcome for T-cell acute lymphoblastic leukemia (T-ALL) in relapse after hematopoietic stem cell transplantation (HSCT) is quite poor, while, both donor lymphocytes infusion (DLI) and adoptively infusion of γδ T cells in leukemia patients after HSCT have demonstrated good results in prolonging s...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189998/ https://www.ncbi.nlm.nih.gov/pubmed/27356746 http://dx.doi.org/10.18632/oncotarget.10260 |
_version_ | 1782487329009565696 |
---|---|
author | Xu, Ling Weng, Jianyu Huang, Xin Zeng, Chengwu Chen, Shaohua Geng, Suxia Yang, Lijian Wu, Suijing Huang, Suming Du, Xin Li, Yangqiu |
author_facet | Xu, Ling Weng, Jianyu Huang, Xin Zeng, Chengwu Chen, Shaohua Geng, Suxia Yang, Lijian Wu, Suijing Huang, Suming Du, Xin Li, Yangqiu |
author_sort | Xu, Ling |
collection | PubMed |
description | The outcome for T-cell acute lymphoblastic leukemia (T-ALL) in relapse after hematopoietic stem cell transplantation (HSCT) is quite poor, while, both donor lymphocytes infusion (DLI) and adoptively infusion of γδ T cells in leukemia patients after HSCT have demonstrated good results in prolonging survival time of patients. Here, we reported a T-ALL case who experienced three relapses and received HSCT and DLI with an overall survival (OS) time lasting for more than seven years. Based on our previous identification of a leukemic and reactive clone in this patient, continual γδ T cell repertoire monitoring affirmed that the same Vδ5 leukemic clone existed in most samples from the patient, particularly including a sample taken at the time of the third T-ALL relapse, while it could not be detected in the donor sample. In addition, an identical Vδ4 monoclonal T cell that proliferated in the recipient for several years was confirmed to come from the donor graft, and its expression level significantly increased in third leukemia recurrence. These results indicate that clonally expanded Vδ4 T cells may represent a reconstituted γδ T cell repertoire after HSCT, which also hints to a relatively better outcome for this case. Based on this case study, we recommend DLI should be as a treatment strategy for patients who achieve CR or relapse from HSCT. Moreover, dynamically monitoring the TCR repertoire in patients who receive HSCT will benefit in supervising of malignant clone evolution and residue, identifying T cell clones mediate anti-infection, GvHD or GvL. |
format | Online Article Text |
id | pubmed-5189998 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-51899982017-01-05 Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI Xu, Ling Weng, Jianyu Huang, Xin Zeng, Chengwu Chen, Shaohua Geng, Suxia Yang, Lijian Wu, Suijing Huang, Suming Du, Xin Li, Yangqiu Oncotarget Research Paper: Immunology The outcome for T-cell acute lymphoblastic leukemia (T-ALL) in relapse after hematopoietic stem cell transplantation (HSCT) is quite poor, while, both donor lymphocytes infusion (DLI) and adoptively infusion of γδ T cells in leukemia patients after HSCT have demonstrated good results in prolonging survival time of patients. Here, we reported a T-ALL case who experienced three relapses and received HSCT and DLI with an overall survival (OS) time lasting for more than seven years. Based on our previous identification of a leukemic and reactive clone in this patient, continual γδ T cell repertoire monitoring affirmed that the same Vδ5 leukemic clone existed in most samples from the patient, particularly including a sample taken at the time of the third T-ALL relapse, while it could not be detected in the donor sample. In addition, an identical Vδ4 monoclonal T cell that proliferated in the recipient for several years was confirmed to come from the donor graft, and its expression level significantly increased in third leukemia recurrence. These results indicate that clonally expanded Vδ4 T cells may represent a reconstituted γδ T cell repertoire after HSCT, which also hints to a relatively better outcome for this case. Based on this case study, we recommend DLI should be as a treatment strategy for patients who achieve CR or relapse from HSCT. Moreover, dynamically monitoring the TCR repertoire in patients who receive HSCT will benefit in supervising of malignant clone evolution and residue, identifying T cell clones mediate anti-infection, GvHD or GvL. Impact Journals LLC 2016-06-23 /pmc/articles/PMC5189998/ /pubmed/27356746 http://dx.doi.org/10.18632/oncotarget.10260 Text en Copyright: © 2016 Xu et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper: Immunology Xu, Ling Weng, Jianyu Huang, Xin Zeng, Chengwu Chen, Shaohua Geng, Suxia Yang, Lijian Wu, Suijing Huang, Suming Du, Xin Li, Yangqiu Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI |
title | Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI |
title_full | Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI |
title_fullStr | Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI |
title_full_unstemmed | Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI |
title_short | Persistent donor derived Vδ4 T cell clones may improve survival for recurrent T cell acute lymphoblastic leukemia after HSCT and DLI |
title_sort | persistent donor derived vδ4 t cell clones may improve survival for recurrent t cell acute lymphoblastic leukemia after hsct and dli |
topic | Research Paper: Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5189998/ https://www.ncbi.nlm.nih.gov/pubmed/27356746 http://dx.doi.org/10.18632/oncotarget.10260 |
work_keys_str_mv | AT xuling persistentdonorderivedvd4tcellclonesmayimprovesurvivalforrecurrenttcellacutelymphoblasticleukemiaafterhsctanddli AT wengjianyu persistentdonorderivedvd4tcellclonesmayimprovesurvivalforrecurrenttcellacutelymphoblasticleukemiaafterhsctanddli AT huangxin persistentdonorderivedvd4tcellclonesmayimprovesurvivalforrecurrenttcellacutelymphoblasticleukemiaafterhsctanddli AT zengchengwu persistentdonorderivedvd4tcellclonesmayimprovesurvivalforrecurrenttcellacutelymphoblasticleukemiaafterhsctanddli AT chenshaohua persistentdonorderivedvd4tcellclonesmayimprovesurvivalforrecurrenttcellacutelymphoblasticleukemiaafterhsctanddli AT gengsuxia persistentdonorderivedvd4tcellclonesmayimprovesurvivalforrecurrenttcellacutelymphoblasticleukemiaafterhsctanddli AT yanglijian persistentdonorderivedvd4tcellclonesmayimprovesurvivalforrecurrenttcellacutelymphoblasticleukemiaafterhsctanddli AT wusuijing persistentdonorderivedvd4tcellclonesmayimprovesurvivalforrecurrenttcellacutelymphoblasticleukemiaafterhsctanddli AT huangsuming persistentdonorderivedvd4tcellclonesmayimprovesurvivalforrecurrenttcellacutelymphoblasticleukemiaafterhsctanddli AT duxin persistentdonorderivedvd4tcellclonesmayimprovesurvivalforrecurrenttcellacutelymphoblasticleukemiaafterhsctanddli AT liyangqiu persistentdonorderivedvd4tcellclonesmayimprovesurvivalforrecurrenttcellacutelymphoblasticleukemiaafterhsctanddli |